CAPECITABINE, BEVACIZUMAB, OXALIPLATIN, CETUXIMAB, FOLINIC ACID, IRINOTECAN, FLUOROURACIL clinical trials

A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial

This study looks at new ways to treat advanced bowel cancer that has specific genetic features. Researchers want to see if combining existing treatments can shrink tumours early and help people live longer, while also improving their quality of life.